Transgenic shRNA pigs reduce susceptibility to foot and mouth disease virus infection

  1. Shengwei Hu
  2. Jun Qiao
  3. Qiang Fu
  4. Chuangfu Chen  Is a corresponding author
  5. Wei Ni
  6. Sai Wujiafu
  7. Shiwei Ma
  8. Hui Zhang
  9. Jingliang Sheng
  10. Pengyan Wang
  11. Dawei Wang
  12. Jiong Huang
  13. Lijuan Cao
  14. Hongsheng Ouyang
  1. Shihezi University, China
  2. Xinjiang Academy of Animal Science, China
  3. Jilin University, China

Abstract

Foot-and-mouth disease virus (FMDV) is an economically devastating viral disease leading to a substantial loss to the swine industry worldwide. A novel alternative strategy is to develop pigs that are genetically resistant to infection. Here, we produce transgenic (TG) pigs that constitutively expressed FMDV-specific siRNA derived from small hairpin RNA (shRNA). In vitro challenge of TG fibroblasts showed the shRNA suppressed viral growth. TG and non-transgenic (Non-TG) pigs were challenged by intramuscular injection with 100 LD50 of FMDV. High fever, severe clinical sign of FMD and typical histopathological changes were observed in all of the Non-TG pigs but in none of the high-siRNA pigs. Our results show that transgenic shRNA can provide a viable tool for producing animals with enhanced resistance to FMDV.

Article and author information

Author details

  1. Shengwei Hu

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Jun Qiao

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Qiang Fu

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Chuangfu Chen

    College of Life Sciences, Shihezi University, Shihezi, China
    For correspondence
    chencf1962@yahoo.com
    Competing interests
    The authors declare that no competing interests exist.
  5. Wei Ni

    College of Animal Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Sai Wujiafu

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Shiwei Ma

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Hui Zhang

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Jingliang Sheng

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Pengyan Wang

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Dawei Wang

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Jiong Huang

    Institute of Veterinary Medicine, Xinjiang Academy of Animal Science, Urumqi, China
    Competing interests
    The authors declare that no competing interests exist.
  13. Lijuan Cao

    College of Life Sciences, Shihezi University, Shihezi, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Hongsheng Ouyang

    College of Animal Science and Veterinary Medicine, Jilin University, Changchun, China
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Stephen P Goff, Howard Hughes Medical Institute, Columbia University, United States

Ethics

Animal experimentation: All experiments involving animals were conducted under the protocol approved by the Animal Care and Use Committee of Shihezi University (SU-ACUC-12031).

Version history

  1. Received: February 10, 2015
  2. Accepted: June 18, 2015
  3. Accepted Manuscript published: June 19, 2015 (version 1)
  4. Version of Record published: July 15, 2015 (version 2)

Copyright

© 2015, Hu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,098
    views
  • 496
    downloads
  • 33
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shengwei Hu
  2. Jun Qiao
  3. Qiang Fu
  4. Chuangfu Chen
  5. Wei Ni
  6. Sai Wujiafu
  7. Shiwei Ma
  8. Hui Zhang
  9. Jingliang Sheng
  10. Pengyan Wang
  11. Dawei Wang
  12. Jiong Huang
  13. Lijuan Cao
  14. Hongsheng Ouyang
(2015)
Transgenic shRNA pigs reduce susceptibility to foot and mouth disease virus infection
eLife 4:e06951.
https://doi.org/10.7554/eLife.06951

Share this article

https://doi.org/10.7554/eLife.06951

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Yi-Shin Chang, Kai Huang ... David L Perkins
    Research Article

    Background:

    End-stage renal disease (ESRD) patients experience immune compromise characterized by complex alterations of both innate and adaptive immunity, and results in higher susceptibility to infection and lower response to vaccination. This immune compromise, coupled with greater risk of exposure to infectious disease at hemodialysis (HD) centers, underscores the need for examination of the immune response to the COVID-19 mRNA-based vaccines.

    Methods:

    The immune response to the COVID-19 BNT162b2 mRNA vaccine was assessed in 20 HD patients and cohort-matched controls. RNA sequencing of peripheral blood mononuclear cells was performed longitudinally before and after each vaccination dose for a total of six time points per subject. Anti-spike antibody levels were quantified prior to the first vaccination dose (V1D0) and 7 d after the second dose (V2D7) using anti-spike IgG titers and antibody neutralization assays. Anti-spike IgG titers were additionally quantified 6 mo after initial vaccination. Clinical history and lab values in HD patients were obtained to identify predictors of vaccination response.

    Results:

    Transcriptomic analyses demonstrated differing time courses of immune responses, with prolonged myeloid cell activity in HD at 1 wk after the first vaccination dose. HD also demonstrated decreased metabolic activity and decreased antigen presentation compared to controls after the second vaccination dose. Anti-spike IgG titers and neutralizing function were substantially elevated in both controls and HD at V2D7, with a small but significant reduction in titers in HD groups (p<0.05). Anti-spike IgG remained elevated above baseline at 6 mo in both subject groups. Anti-spike IgG titers at V2D7 were highly predictive of 6-month titer levels. Transcriptomic biomarkers after the second vaccination dose and clinical biomarkers including ferritin levels were found to be predictive of antibody development.

    Conclusions:

    Overall, we demonstrate differing time courses of immune responses to the BTN162b2 mRNA COVID-19 vaccination in maintenance HD subjects comparable to healthy controls and identify transcriptomic and clinical predictors of anti-spike IgG titers in HD. Analyzing vaccination as an in vivo perturbation, our results warrant further characterization of the immune dysregulation of ESRD.

    Funding:

    F30HD102093, F30HL151182, T32HL144909, R01HL138628. This research has been funded by the University of Illinois at Chicago Center for Clinical and Translational Science (CCTS) award UL1TR002003.